SELLAS Life Sciences Group, Inc. (SLS)
- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $10.38
- As of
Kresmion compiles this page from SLS's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
SELLAS Life Sciences Group, Inc. (SLS): 1 institutional manager tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 10-Q filed 2026-08-11.
See the full SLS dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for SLS on one page. Preview it with sample data, then open it live with a free account.
Preview the SLS dossierActive events for SLS
- high13F: large increase
CITADEL ADVISORS LLC added +2235% to SLS (2026Q2)
- high13F: large increase
CITADEL ADVISORS LLC added +4395% to SLS (2026Q2)
- high13F: large reduction
MILLENNIUM MANAGEMENT LLC cut 69% of SLS (2026Q2)
- mediumEarnings above estimates
Q2-2025: Beat consensus by 15.9% - EPS $-0.07 vs $-0.0832 estimate
- mediumEarnings above estimates
Q3-2025: Beat consensus by 10.0% - EPS $-0.06 vs $-0.0667 estimate
FREE, NO ACCOUNT
Every event on SLS, as it fires
You are seeing 5 of 7 events recorded on SLS since 2026-06-02.
The five above landed across 2 days. The other 2 were recorded on those same days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in SLS (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| RENAISSANCE TECHNOLOGIES LLCCUSIP 81642T209 · 2026Q2 | $4.6M | 0.01% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, SLS
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
SLS against its peers
SLS's return on equity of -37.9% ranks in the 52nd percentile of 19 Biotechnology sub-industry peers, fiscal period ending 2025-12-31.
| Metric | SLS | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | n/a | 67.7M | n/a | 15 |
| Gross margin | n/a | 92.9% | n/a | 6 |
| Operating margin | n/a | -400.1% | n/a | 16 |
| Net margin | n/a | -358.1% | n/a | 16 |
| Return on equity | -37.9% | -49.6% | 53 | 19 |
Peers (20): SRPT, ABSI, VIR, SEPN, ZYME, VCEL, LKFT, PVLA, BCRX, PGEN, MLYS, IMNM, ZBIO, VERA, XNCR, NTLA, AGIO, PHVS, AUPH, RCUS. Left out: ADRX (no annual filing), GENB (no annual filing), BRVE (no annual filing), TRAX (no annual filing), ZLDPF (no annual filing). Fiscal period ending 2025-12-31. Every figure is one full fiscal year read from one annual filing (SLS: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow SLS on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to SLS for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.